Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 4, 2002, Pages 429-437

  Wuttke, Henrike ^a,b,c   Rau, Thomas ^a,b,c   Heide, Roland ^a,b,c   Bergmann, Klaus ^a,b,c   Böhm, Michael ^a,b,c   Weil, Joachim ^a,b,c   Werner, Dierk ^a,b,c   Eschenhagen, Thomas ^a,b,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARVEDILOL; CYTOCHROME P450 2D6; FLUOXETINE; METOPROLOL; PAROXETINE; PROPAFENONE; QUINIDINE;

ADULT; AGED; ARTICLE; ASYSTOLE; ATRIOVENTRICULAR BLOCK; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; FEMALE; GENOTYPE; GERMANY; HEADACHE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; MALE; MIGRAINE; NAUSEA; NIGHTMARE; NULL ALLELE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; VERTIGO;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0036795977     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.127111     Document Type: Article

References (47)

1. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
2. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
3. Helm MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992;14:49-58.
4. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-96.
5. Zanger UM, Eichelbaum M. CYP2D6. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 87-94.
6. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
7. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
8. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
9. CYP2D6 allele nomenclature. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at: http://www.imm.ki.se/CYPalleles/cyp2d6.htm. Accessed March 15, 2002.
10. Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-37.
11. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, et al. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY Study. Hypertension 1991;17:579-88.
12. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
13. Lemmer B. Betarezeptorenblocker. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report 2000. Berlin: Springer-Verlag; 2001. p. 257-66.
14. Borg KO, Carlsson E, Hoffmann KJ, Jönsson TE, Thorin H, Wallin B. Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol (Copenh) 1975; 36:125-35.
15. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med 1982;307:1558-60.
16. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br J Clin Pharmacol 1985;20:555-66.
17. Kendall MJ, Maxwell SR, Sandberg A, Westergren G. Controlled release metoprolol: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991; 21:319-30.
18. Freestone S, Silas JH, Lennard MS, Ramsay LE. Com-parison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol 1982; 14:713-8.
19. Deroubaix X, Lins RL, Lens S, Demblon C, Jeanbaptiste B, Poelaert D, et al. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers. Int J Clin Pharmacol Ther 1996;34:61-70.
20. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
21. Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 1987;24:213-20.
22. Clark DW, Morgan AK, Waal-Manning H. Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 1984;18:965-7.
23. Leemann T, Dayer P, Meyer UA. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 1986;29:739-41.
24. Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 1986;22:194-7.
25. Brøsen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987;60:312-4.
26. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000;40:58-66.
27. Sachse C, Brockmöller J, Hildebrand M, Muller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998;8:181-5.
28. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
29. Løvlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001;11:45-55.
30. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000;10:577-81.
31. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465-72.
32. Bock KW, Schrenk D, Froster A, Griese EU, Mörike K, Brockmeier D, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics 1994;4:209-18.
33. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92.
34. Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999;9:301-9.
35. Kirch W, Spahn H, Kitteringham NR, Hutt HJ, Mutschler E, Ohnhaus EE. Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism. Br J Clin Pharmacol 1984;17(suppl 1):65-8.
36. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992;14:1-8.
37. LLerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl ML. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993;54:606-11.
38. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999;27:1078-84.
39. Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, et al. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 2001;23:228-31.
40. Brøsen K. Antiarrhythmics. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 603-14.
41. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000;49:244-53.
42. Funck-Brentano C, Jacqz-Aigrain E, Leenhardt A, Roux A, Poirier JM, Jaillon P. Influence of amiodarone on genetically determined drug metabolism in humans. Clin Pharmacol Ther 1991;50:259-66.
43. Leor J, Levartowsky D, Sharon C, Farfel Z. Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol. Am Heart J 1988;116:206-7.
44. Bengtsson C, Johnsson G, Regardh CG. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther 1975;17:400-8.
45. von Bahr C, Collste P, Frisk-Holmberg M, Haglund K, Jorfelt L, Orme M, et al. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension. Clin Pharmacol Ther 1976;20:130-7.
46. Gottlieb SS, Fisher ML, Kjekshus J, Deedwania P, Gullestad L, Vitovec J, et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002;105:1182-8.
47. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-34.